Psomagen (XKRX:950200) Debt-to-Asset : 0.11 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Psomagen Debt-to-Asset?

Psomagen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩1,604 Mil. Psomagen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩3,304 Mil. Psomagen's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₩44,124 Mil. Psomagen's debt to asset for the quarter that ended in Mar. 2024 was 0.11.

Psomagen Debt-to-Asset Historical Data

The historical data trend for Psomagen's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psomagen Debt-to-Asset Chart

Psomagen Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.80

0.16

0.11

Psomagen Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial														0.10	0.10	0.11	0.11	0.11

Competitive Comparison of Psomagen's Debt-to-Asset

For the Diagnostics & Research subindustry, Psomagen's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psomagen's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Psomagen's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Psomagen's Debt-to-Asset falls into.

Psomagen Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Psomagen's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1506.71	+	3482.757)	/	44597.143
	=	0.11

Psomagen's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1603.936	+	3304.398)	/	44123.588
	=	0.11

Psomagen (XKRX:950200) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Psomagen Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Psomagen's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Psomagen (XKRX:950200) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psomagen Inc (XKRX:950200) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1330 Piccard Drive, Suite 103, Rockville, MD, USA, 20850

Website

https://www.psomagen.com

Psomagen Inc, formerly Macrogen Corp provides total genomic solutions for both clinical and research purposes. It is mainly focused on end-to-end sequencing services. The company also offers services such as personal DNA tests, clinical sequencing, research sequencing, and others.

Psomagen (XKRX:950200) Headlines

No Headlines